topic

Silence of a dependence receptor CSF1R in colorectal cancer cells activates tumor-associated macrophages
Mingxuan Zhu, Liangliang Bai, Xiaoxia Liu, Shaoyong Peng, Yumo Xie, Hong Bai, Huichuan Yu, Xiaolin Wang, Ping Yuan, Rui Ma, Jinxin Lin, Linping Wu, Meijin Huang, Yingjie Li, Yanxin Luo

Journal for ImmunoTherapy of Cancer Dec 2022, 10 (12) e005610; DOI: 10.1136/jitc-2022-005610
Targeting of colorectal cancer organoids with zoledronic acid conjugated to the anti-EGFR antibody cetuximab
Roberto Benelli, Delfina Costa, Laura Salvini, Samuele Tardito, Francesca Tosetti, Federico Villa, Maria Raffaella Zocchi, Alessandro Poggi

Journal for ImmunoTherapy of Cancer Dec 2022, 10 (12) e005660; DOI: 10.1136/jitc-2022-005660
Correction: Defining unique clinical hallmarks for immune checkpoint inhibitor-based therapies
Journal for ImmunoTherapy of Cancer Dec 2022, 10 (12) e003024corr1; DOI: 10.1136/jitc-2021-003024corr1
Immune responses against shared antigens are common in esophago-gastric cancer and can be enhanced using CD40-activated B cells
Martin Thelen, Diandra Keller, Jonas Lehmann, Kerstin Wennhold, Hendrik Weitz, Eugen Bauer, Birgit Gathof, Monika Brüggemann, Michaela Kotrova, Alexander Quaas, Christoph Mallmann, Seung-Hun Chon, Axel M Hillmer, Christiane Bruns, Michael von Bergwelt-Baildon, Maria Alejandra Garcia-Marquez, Hans Anton Schlößer

Journal for ImmunoTherapy of Cancer Dec 2022, 10 (12) e005200; DOI: 10.1136/jitc-2022-005200
Modification of PLAC8 by UFM1 affects tumorous proliferation and immune response by impacting PD-L1 levels in triple-negative breast cancer
Misha Mao, Yongxia Chen, Jingjing Yang, Yifan Cheng, Ling Xu, Feiyang Ji, Jichun Zhou, Xun Zhang, Zhaoqing Li, Cong Chen, Siwei Ju, Jiahang Zhang, Linbo Wang

Journal for ImmunoTherapy of Cancer Dec 2022, 10 (12) e005668; DOI: 10.1136/jitc-2022-005668
Dasatinib for treatment of CAR T-cell therapy-related complications
Katharina Baur, Dominik Heim, Astrid Beerlage, Anna S Poerings, Bastian Kopp, Michael Medinger, Jan C Dirks, Jakob R Passweg, Andreas Holbro

Journal for ImmunoTherapy of Cancer Dec 2022, 10 (12) e005956; DOI: 10.1136/jitc-2022-005956
Fibrolamellar carcinoma transcriptomic-based treatment prediction: complete response after nivolumab and ipilimumab
Raanan Berger, Gal Dinstag, Omer Tirosh, Eyal Schiff, David Kleiner, Kenneth D Aldape, Eytan Ruppin, Tuvik Beker, Razelle Kurzrock

Journal for ImmunoTherapy of Cancer Dec 2022, 10 (12) e005620; DOI: 10.1136/jitc-2022-005620
Modeling resistance of colorectal peritoneal metastases to immune checkpoint blockade in humanized mice
Emre Küçükköse, Balthasar A Heesters, Julien Villaudy, André Verheem, Madalina Cercel, Susan van Hal, Sylvia F Boj, Inne H M Borel Rinkes, Cornelis J A Punt, Jeanine M L Roodhart, Jamila Laoukili, Miriam Koopman, Hergen Spits, Onno Kranenburg

Journal for ImmunoTherapy of Cancer Dec 2022, 10 (12) e005345; DOI: 10.1136/jitc-2022-005345
Update in the treatment of non-melanoma skin cancers: the use of PD-1 inhibitors in basal cell carcinoma and cutaneous squamous-cell carcinoma
Paolo A Ascierto, Dirk Schadendorf

Journal for ImmunoTherapy of Cancer Dec 2022, 10 (12) e005082; DOI: 10.1136/jitc-2022-005082
Correspondence on 'Outcomes of stage IV melanoma in the era of immunotherapy: a National Cancer Database (NCDB) analysis from 2014 to 2016' by Sussman et al
Christopher Grant, Garo Hagopian, Thuy B Tran, Gayathri Nagaraj, Justin T Moyers

Journal for ImmunoTherapy of Cancer Dec 2022, 10 (12) e006187; DOI: 10.1136/jitc-2022-006187

Main menu

topic

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

topic

Pages